0
0
KARACHI, Pakistan — Health authorities in Sindh province confirmed on Tuesday that a 31-year-old male traveler has tested positive for mpox, marking the first recorded case of the virus in Pakistan’s largest city for the 2026 calendar year. While the patient has already been treated and discharged, the development has triggered a nationwide intensification of surveillance protocols as officials work to distinguish between imported infections and a brewing threat of community transmission.
The patient, who recently arrived from abroad, was identified during mandatory health screenings at Jinnah International Airport after presenting with symptoms indicative of the virus. He was immediately transported to the Sindh Infectious Diseases Hospital (SIDH) for isolation and diagnostic confirmation. Medical Superintendent Dr. Waheed Rajput confirmed the diagnosis following a clinical examination and laboratory testing. After responding favorably to supportive care, the patient was discharged within 48 hours, signaling a success for the city’s early intervention strategy.
A Growing Pattern of Infection
The emergence of this case follows a year of increased viral activity. In 2025, Pakistan documented 53 confirmed cases of mpox, the majority of which were detected through rigorous airport border controls. However, the 2026 landscape has already shown signs of shifting complexity. In February, a 53-year-old man from Faisalabad succumbed to the virus. Notably, the deceased had no recent travel history and suffered from underlying comorbidities, including HIV and hepatitis, raising significant concerns among epidemiologists regarding undetected local chains of transmission.
“This Karachi case was managed swiftly due to our robust screening protocols,” stated Dr. Rajput. “Our facility, which was strengthened during the COVID-19 pandemic, is fully equipped for infectious disease management. However, the priority now is ensuring that every entry point and local clinic remains vigilant.”
Understanding Mpox: The Viral Profile
Mpox, a viral zoonotic disease caused by the monkeypox virus, belongs to the Orthopoxvirus genus—the same family as the virus that causes smallpox. While the disease has been endemic to Central and West Africa for decades, a global multi-country outbreak beginning in 2022 prompted the World Health Organization (WHO) to declare several Public Health Emergencies of International Concern (PHEIC).
The virus is categorized into two distinct genetic clades: Clade I and Clade II. While Clade II was responsible for the initial 2022 global surge, the more recent 2023–2026 epidemic has seen the rise of Clade Ib, which has been driving severe outbreaks in parts of Africa and showing increased efficiency in human-to-human transmission.
Transmission and Symptoms:
The virus spreads primarily through close, personal, often skin-to-skin contact. This includes:
-
Direct contact with mpox rash, scabs, or body fluids.
-
Prolonged face-to-face contact (respiratory droplets).
-
Contact with contaminated objects, such as bedding, towels, or clothing used by an infected person.
Symptoms typically begin with a “prodromal” phase consisting of fever, intense headache, muscle aches, and distinctive swelling of the lymph nodes—a feature that often differentiates mpox from chickenpox. Within one to three days of the fever, a rash develops, often beginning on the face or genitals before spreading. The lesions progress through several stages, from flat spots to painful fluid-filled blisters, before eventually crusting over and falling off. The entire illness typically lasts two to four weeks.
Expert Perspectives on Risk and Management
Medical professionals emphasize that while the word “outbreak” causes anxiety, mpox is significantly less transmissible than respiratory viruses like COVID-19.
“With optimal supportive care, mortality can drop significantly even without the use of specific antivirals,” says Dr. Jason Zucker, an infectious disease specialist at Columbia University. Dr. Zucker notes that while vaccines such as Jynneos or ACAM2000 are effective at reducing the risk of severe disease, they are not a “silver bullet” and should be used in conjunction with behavioral Precautions. “Vaccination reduces risk, though it doesn’t fully prevent infection in every case.”
In Pakistan, the challenge remains one of resources and reach. Experts from the Dow University of Health Sciences have called for enhanced international cooperation to ensure that diagnostic kits and vaccines are available to frontline workers and high-risk populations.
Public Health Response and Practical Advice
The Sindh and federal health ministries have activated strict contact tracing and laboratory testing protocols in response to the Karachi case. Currently, Pakistan follows WHO-standardized guidelines for management:
-
Isolation: Patients with mild symptoms may isolate at home if they can stay in a separate room and avoid contact with household members and pets.
-
Symptom Relief: Treatment focuses on hydration, pain management, and preventing secondary bacterial infections of the skin lesions.
-
Severe Cases: For immunocompromised individuals, antiviral treatments like tecovirimat may be considered, though availability is often limited to specialized centers.
For the general public, health officials advise maintaining standard hygiene practices, such as frequent handwashing, and avoiding close contact with individuals who exhibit unexplained rashes.
Looking Ahead: Limitations and Challenges
Despite the successful isolation of the Karachi traveler, gaps remain. Critics of the current surveillance system point out that 53 cases in a population of over 240 million likely represents an undercount. In low-resource or rural areas, skin rashes may be misdiagnosed or go unreported, allowing community spread to persist silently.
Furthermore, while the recovery rate for healthy adults exceeds 99%, the risk remains high for vulnerable groups, including children, pregnant people, and those with weakened immune systems. The death in Faisalabad earlier this year serves as a stark reminder that for those with co-infections like HIV, mpox can be fatal.
As of early 2026, the WHO maintains a “moderate” global risk assessment. For Pakistan, the goal is clear: prevent the virus from establishing a permanent foothold in the local population through aggressive screening and transparent public communication.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
Studies and Reports:
- https://www.punjabnewsexpress.com/news/news/pakistans-karachi-reports-its-first-case-of-mpox-this-year-321445
